Researchers around the world are working on the development of drugs to treat and prevent the novel coronavirus. The number of newly initiated clinical trials has accordingly risen by 51 percent over the past week, as revealed by data from Intrepida. The start-up has now launched an initiative by the name of Ancora.ai that is set to help in the recruitment of patients for these studies.
Ancora.ai is based on Artificial Intelligence (AI) and aims to make recruiting patients easier and faster, as detailed in a press release. Potential participants can complete a questionnaire via the app and are automatically matched with relevant clinical trial options. Users can also track the progress of clinical trials via Ancora.ai.
"We have been working in healthcare for a long time and saw a gap between clinical trials and the patients who would most benefit from participating in research”, comments Danielle Ralic, CEO of Intrepida, in the press release, before adding: “We designed Ancora.ai to bridge that gap”.
Intrepida was founded in 2017 and its headquarters are located in Zurich. The company develops a wide range of AI-based applications for the healthcare sector.
